Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
3
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
4
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
5